Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus

Accepted/In Press date: 16 August 2022

Published date: 6 September 2022

Additional Information: Funding Information: We thank Rosemarie Mason and Mario Roederer at NIH, David Montefiori at Duke University, and Cynthia Derdeyn at Emory University for providing the SIV pseudovirus envelope plasmids. We thank Louis Picker at Oregon Health & Science University for providing the non-neutralizing SIVmac239-infected macaque plasma samples. We thank Matthias Pauthner for testing the plasma nAb titers from previous infected rhesus samples and the staff of the Quantitative Molecular Diagnostics Core of the AIDS and Cancer Virus Program, Frederick National Laboratory for technical assistance with viral load measurements. This work is supported by the National Institute of Allergy and Infectious Diseases (NIAID) Consortium for HIV/AIDS Vaccine Development (CHAVD; UM1AI144462) (M.C., A.B.W., D.R.B., and D.S.), the Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (INV-008352/OPP1153692 and OPP1196345/INV-008813) (D.S., D.R.B., A.B.W., and R.A.), and the NIH R61 AI161818 (R.A.); in part by NIH Grant R61 AI161818 (R.A.), NIH RO1 AI 52056-20 (D.I.W.), and Federal funds from the National Cancer Institute, National Institutes of Health, under Contract Nos. HHSN261201500003I and 75N91019D00024 (J.D.L.). This work is also supported in part by the Office of The Director, National Institutes of Health under Award Number P51OD011106 to the Wisconsin National Primate Research Center, University of Wisconsin-Madison. This research was conducted in part at a facility constructed with support from Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01. Funding Information: We thank Rosemarie Mason and Mario Roederer at NIH, David Montefiori at Duke University, and Cynthia Derdeyn at Emory University for providing the SIV pseudovirus envelope plasmids. We thank Louis Picker at Oregon Health & Science University for providing the non-neutralizing SIVmac239-infected macaque plasma samples. We thank Matthias Pauthner for testing the plasma nAb titers from previous infected rhesus samples and the staff of the Quantitative Molecular Diagnostics Core of the AIDS and Cancer Virus Program, Frederick National Laboratory for technical assistance with viral load measurements. This work is supported by the National Institute of Allergy and Infectious Diseases (NIAID) Consortium for HIV/AIDS Vaccine Development (CHAVD; UM1AI144462) (M.C., A.B.W., D.R.B., and D.S.), the Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (INV-008352/OPP1153692 and OPP1196345/INV-008813) (D.S., D.R.B., A.B.W., and R.A.), and the NIH R61 AI161818 (R.A.); in part by NIH Grant R61 AI161818 (R.A.), NIH RO1 AI 52056-20 (D.I.W.), and Federal funds from the National Cancer Institute, National Institutes of Health, under Contract Nos. HHSN261201500003I and 75N91019D00024 (J.D.L.). This work is also supported in part by the Office of The Director, National Institutes of Health under Award Number P51OD011106 to the Wisconsin National Primate Research Center, University of Wisconsin-Madison. This research was conducted in part at a facility constructed with support from Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01. Publisher Copyright: © 2022, The Author(s).

Keywords: Animals, Antibodies, Neutralizing, Antibodies, Viral, HIV Infections/prevention & control, Humans, Macaca mulatta, Polysaccharides, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus

Local EPrints ID: 472334

URI: http://eprints.soton.ac.uk/id/eprint/472334

DOI: doi:10.1038/s41467-022-32783-2

ISSN: 2041-1723

PURE UUID: 5c1e112c-e37d-40b6-84fe-f827c9096221

ORCID for Joel D. Allen: orcid.org/0000-0003-2547-968X

ORCID for Max Crispin: orcid.org/0000-0002-1072-2694

Date deposited: 01 Dec 2022 17:43

Last modified: 17 Mar 2024 04:09